Compare Home Depot Inc (HD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Home Depot Inc trades at $296.22 (market cap $293.24B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Home Depot Inc is far larger — about 301.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Home Depot Inc pays a 3.17% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HD | MRVI | |
|---|---|---|
Market Cap | $293.24B | $972.90M |
Volume | 4,521,013 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $9.00 |
52-Week Low | $281.15 | $2.83 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $353.72B | $1.08B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $295.51, up 1.68% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bearish technical signals but maintains solid fundamentals with $159.51B revenue and 8.41% net margin. Recent institutional activity shows mixed positioning while analyst consensus remains bullish with a $379.93 price target.
HD offers value with reasonable valuation multiples (P/E 20.57) and consistent profitability, though margin compression and housing market sensitivity pose risks. The 58.73% buy rating from analysts suggests upside potential, but investors should monitor Pro segment performance amid weakening big-ticket demand.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
